OBJECTIVE: This work aimed at building a population pharmacokinetic (PK) model for lamivudine (LMV), stavudine (STV) and zidovudine (ZDV), estimating their inter and intraindividual PK variability and investigating the influence of different covariates. METHODS: Population PK of LMV, STV and ZDV was separately evaluated from plasma concentrations obtained in 54, 39 and 27 HIV1-infected patients, respectively, enrolled in the COPHAR1-ANRS102 trial. The primary objective of this trial was to study the pharmacokinetics of indinavir (IDV) and nelfinavir (NFV) in treated patients with a sustained virological response. Concentrations of nucleoside analogs (NA) were measured in plasma as a secondary objective. A one-compartment model with first-order elimination was used, with zero-order absorption for LMV and first-order absorption for STV and ZDV. RESULTS: Mean parameters [interpatient variability in coefficient of variation (CV%)] of LMV, STV and ZDV were: oral volume of distribution (V/F) 145 l (52%), 24 l (81%) and 248 l (80%), oral clearance (Cl/F) 32 l/h, 16 l/h (74%) and 124 l/h (51%), respectively. For LMV, absorption duration (Ta) was 1.46 h (64%). For STV and ZDV, ka was 0.46 h(-1) and 2.9 h(-1), respectively. We found a systematic effect of combination with NFV vs. IDV. We found that intrapatient variability was greater than interpatient variability (except for STV) and greater than 55% for the three drugs. CONCLUSION: This trial enabled the estimation of the population PK parameters of three NA in patients with a sustained virological response, and the median curves could be used as references for concentration-controlled strategies. We observed, as for the protease inhibitors, a great variability of PK parameters.
OBJECTIVE: This work aimed at building a population pharmacokinetic (PK) model for lamivudine (LMV), stavudine (STV) and zidovudine (ZDV), estimating their inter and intraindividual PK variability and investigating the influence of different covariates. METHODS: Population PK of LMV, STV and ZDV was separately evaluated from plasma concentrations obtained in 54, 39 and 27 HIV1-infectedpatients, respectively, enrolled in the COPHAR1-ANRS102 trial. The primary objective of this trial was to study the pharmacokinetics of indinavir (IDV) and nelfinavir (NFV) in treated patients with a sustained virological response. Concentrations of nucleoside analogs (NA) were measured in plasma as a secondary objective. A one-compartment model with first-order elimination was used, with zero-order absorption for LMV and first-order absorption for STV and ZDV. RESULTS: Mean parameters [interpatient variability in coefficient of variation (CV%)] of LMV, STV and ZDV were: oral volume of distribution (V/F) 145 l (52%), 24 l (81%) and 248 l (80%), oral clearance (Cl/F) 32 l/h, 16 l/h (74%) and 124 l/h (51%), respectively. For LMV, absorption duration (Ta) was 1.46 h (64%). For STV and ZDV, ka was 0.46 h(-1) and 2.9 h(-1), respectively. We found a systematic effect of combination with NFV vs. IDV. We found that intrapatient variability was greater than interpatient variability (except for STV) and greater than 55% for the three drugs. CONCLUSION: This trial enabled the estimation of the population PK parameters of three NA in patients with a sustained virological response, and the median curves could be used as references for concentration-controlled strategies. We observed, as for the protease inhibitors, a great variability of PK parameters.
Authors: K H Moore; S Shaw; A L Laurent; P Lloyd; B Duncan; D M Morris; M J O'Mara; G E Pakes Journal: J Clin Pharmacol Date: 1999-06 Impact factor: 3.126
Authors: J M Adams; M J Shelton; R G Hewitt; M DeRemer; R DiFrancesco; T H Grasela; G D Morse Journal: Antimicrob Agents Chemother Date: 1998-02 Impact factor: 5.191
Authors: C V Fletcher; E P Acosta; K Henry; L M Page; C R Gross; S P Kawle; R P Remmel; A Erice; H H Balfour Journal: Clin Pharmacol Ther Date: 1998-09 Impact factor: 6.875
Authors: X J Zhou; L B Sheiner; R T D'Aquila; M D Hughes; M S Hirsch; M A Fischl; V A Johnson; M Myers; J P Sommadossi Journal: Antimicrob Agents Chemother Date: 1999-01 Impact factor: 5.191
Authors: C Bazzoli; H Bénech; E Rey; S Retout; D Salmon; X Duval; J M Tréluyer; F Mentré Journal: Antimicrob Agents Chemother Date: 2011-05-16 Impact factor: 5.191
Authors: Adriana H Tremoulet; Mina Nikanjam; Tim R Cressey; Kulkanya Chokephaibulkit; Ross McKinney; Mark Mirochnick; Edmund V Capparelli Journal: J Clin Pharmacol Date: 2011-12-16 Impact factor: 3.126
Authors: Sherwin K B Sy; Steve Innes; Hartmut Derendorf; Mark F Cotton; Bernd Rosenkranz Journal: Antimicrob Agents Chemother Date: 2013-12-02 Impact factor: 5.191
Authors: Awewura Kwara; Margaret Lartey; Isaac Boamah; Naser L Rezk; Joseph Oliver-Commey; Ernest Kenu; Angela D M Kashuba; Michael H Court Journal: J Clin Pharmacol Date: 2009-07-23 Impact factor: 3.126